The Oncology Institute Announces Certification to Administer Pluvicto Therapy in California
12 November 2024 - 12:00AM
Today, the Oncology Institute, Inc. and its affiliates (NASDAQ:
TOI) announced that they have received certification to begin
administering Pluvicto therapy in their outpatient California
radiation oncology practices. Pluvicto, a radiopharmaceutical used
to treat certain types of metastatic prostate cancer, has
previously been administered primarily in hospital settings.
“We are ecstatic about the opportunity to offer this new
therapeutic alternative to our patients,” said Dr. Geoffrey Geiger,
Medical Director of Radiation Oncology at TOI. “This aligns
perfectly with TOI’s mission to deliver state-of-the-art therapy in
the community and provide value for our patients and payor
partners.”
Jeremy Castle, Chief Operations Officer, added, “The launch of
our radiopharmaceutical program marks a significant step forward in
our radiation oncology growth strategy. By providing this treatment
in the outpatient setting, we can reduce the need for costly
hospitalizations, benefiting patients, payors, and our organization
alike. It’s a win for all involved”
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly
specialized, value-based cancer care in the community setting. TOI
offers cutting-edge, evidence-based cancer care to a population of
over 1.8 million patients including clinical trials, transfusions,
and other services traditionally associated with the most advanced
care delivery organizations. With over 120 employed clinicians and
more than 700 teammates in over 70 clinic locations, TOI is
changing oncology for the better. For more information
visit www.theoncologyinstitute.com.
Investors
Solebury Strategic
Communicationsinvestors@theoncologyinstitute.com
Oncology Institute (NASDAQ:TOIIW)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oncology Institute (NASDAQ:TOIIW)
Historical Stock Chart
From Dec 2023 to Dec 2024